Last reviewed · How we verify
CTX112
At a glance
| Generic name | CTX112 |
|---|---|
| Sponsor | CRISPR Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease (PHASE1)
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CTX112 CI brief — competitive landscape report
- CTX112 updates RSS · CI watch RSS
- CRISPR Therapeutics portfolio CI